Sugi Predict

Sugi Predict / Compounds / SCHEMBL2583686

SCHEMBL2583686

SCHEMBL2583686

COc1ccc(Br)c(OC)c1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.56
▸ ALOX15 P16050 2/20 0.47
▸ ALOX12 P18054 2/20 0.47
▸ MAPT P10636 3/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ ALOX5 P09917 1/20 0.45
▸ PTGS2 P35354 1/20 0.45
▸ AMY1A P0DUB6 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ TP53 P04637 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ TUBB1 Q9H4B7 7/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ TUBB4A P04350 4/20 0.42
▸ TUBB P07437 4/20 0.42
▸ TUBA3C P0DPH7 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31096354 1.00 ERN1 (0.56) ERN1ALOX15ALOX12MAPTCYP3A4
SCHEMBL2589132 0.83 MAPT (0.53) ERN1ALOX15ALOX12MAPTCYP3A4
SCHEMBL2588497 0.82 ERN1 (0.60) ERN1ALOX15ALOX12MAPTCYP3A4
SCHEMBL1402474 0.81 MAPT (0.61) ERN1ALOX15ALOX12MAPTCYP3A4
SCHEMBL2591598 0.81 ERN1 (0.47) ERN1ALOX15ALOX12MAPTCYP3A4
SCHEMBL772484 0.79 CA2 (0.50) ERN1MAPTCYP3A4ALDH1A1KDM4E
SCHEMBL30171329 0.79 CA2 (0.50) ERN1MAPTCYP3A4ALDH1A1KDM4E
SCHEMBL14363464 0.78 ERN1 (0.56) ERN1ALOX15ALOX12MAPTCYP3A4
SCHEMBL9109330 0.77 TUBB1 (0.47) ERN1MAPTCYP3A4ALDH1A1KDM4E
SCHEMBL5349727 0.77 CYP3A4 (0.54) ALOX15ALOX12MAPTCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3861001-B1 BORON CONTAINING PDE4 INHIBITORS PFIZER (US) 2023-12-13 — — EP disclosed
EP-3861001-B1 BORON CONTAINING PDE4 INHIBITORS PFIZER (US) 2023-12-13 — — EP disclosed
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 — — US disclosed
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 — — US disclosed
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 — — US disclosed
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PFIZER INC. (US) 2023-01-24 — — US disclosed
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PFIZER INC. (US) 2023-01-24 — — US disclosed
EP-3861001-A1 BORON CONTAINING PDE4 INHIBITORS Pfizer Inc. (US) 2021-08-11 — — EP disclosed
CN-113166177-A Boron-containing PDE4 inhibitors 辉瑞公司 2021-07-23 — — CN disclosed
US-10946031-B2 PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol PFIZER INC. (US) 2021-03-16 — — US disclosed
US-20210069219-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2021-03-11 — — US disclosed
WO-2020070651-A1 BORON CONTAINING PDE4 INHIBITORS PFIZER INC. (US) 2020-04-09 — — WO disclosed
US-20200108083-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2020-04-09 — — US disclosed
US-20200108083-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2020-04-09 — — US disclosed
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 — — EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 — — US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 — — US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 — — EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 — — WO disclosed
US-4182912-A BROMINATION OF PYROGALLOL 1,3-DIMETHYL ETHER WITH N-BROMOSUCCINIMIDE IN THE PRESENCE OF HALOGENATED HYDROCARBON AND ALKYL ALCOHOL POLAROID CORPORATION (US) 1980-01-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PDE4B, PDE4A, PDE3B ERN1 3025/4885ALOX15 1402/4885ALOX12 1501/4885
US-20210069219-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B ERN1 3340/4885ALOX15 2719/4885ALOX12 3314/4885
US-20200108083-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B ERN1 3340/4885ALOX15 2719/4885ALOX12 3314/4885
US-20230148402-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B ERN1 3340/4885ALOX15 2719/4885ALOX12 3314/4885
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A ERN1 1872/4885ALOX15 1181/4885ALOX12 1136/4885
US-10946031-B2 PDE4 inhibitor (R)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol PDE4A, PDE4B, PDE12 ERN1 3590/4885ALOX15 2595/4885ALOX12 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.